ALGS
NASD Aligos Therapeutics, Inc.$5.62 ↑ +0.12 (+2.18%) Trading Up from the previous close of $5.50, $0.10 below the day’s high of $5.72
- YTD change
- -39.70%
- vs 20-day SMA
- +2.36%
- vs 200-day SMA
- -16.56%
Price ranges
Price & Performance
-2.47 (-30.99%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.4% away from all-time highs of $937.75
- ALGS is down 40% since the beginning of the year
- ALGS is down 45% over the past 12 months
- ALGS is down 10% over the past 1 month
- 13% of all ALGS investors are betting against ALGS
ALGS reads neutral: price sits above one of the two key moving averages, the 12-month move is -46.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.20
- Last 5 days
- +1.26%
- vs 8-day SMA
- +0.83%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
